• Теги
    • избранные теги
    • Компании1087
      • Показать ещё
      Разное281
      • Показать ещё
      Страны / Регионы265
      • Показать ещё
      Международные организации32
      • Показать ещё
      Формат17
      Люди27
      • Показать ещё
      Показатели36
      • Показать ещё
      Издания13
      • Показать ещё
Novo Nordisk
20 сентября, 17:12

Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

14 сентября, 16:21

The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

14 сентября, 00:23

Top Analyst Reports for Apple, Pfizer & Carnival

Top Analyst Reports for Apple, Pfizer & Carnival

11 сентября, 15:17

Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?

Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).

26 июня, 16:30

The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

26 июня, 12:59

New Roche haemophilia drug prevents bleeds but questions remain

Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.

23 июня, 14:42

Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

22 июня, 17:57

Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

22 июня, 01:18

Top Analyst Reports for Caterpillar, Intel & Monsanto

Top Analyst Reports for Caterpillar, Intel & Monsanto

21 июня, 18:17

Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.

16 июня, 21:26

Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

14 июня, 22:34

Political Uncertainty in Finland: ETFs in Focus

The ruling coalition is at risk as Finns appointed anti-immigration Jussi Halla-aho as the leader of their party.

14 июня, 16:09

Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

12 июня, 15:43

Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

05 июня, 14:47

Key FDA Events to Watch Out for in Jun 2017

Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

Выбор редакции
01 июня, 21:06

Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B

Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.

31 мая, 23:05

Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

30 мая, 18:12

Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

Выбор редакции